Author

Cari A. Young

City Of Hope National Medical CenterORCID 0000-0002-0733-7816Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Handan Hong· 2 shared Jiangyue LiuiD· 2 shared Jingting Hao· 2 shared John Paul MuradiD· 2 shared Lea ChristianiD· 2 shared Lupita Lopez· 2 shared Reginaldo RosaiD· 2 shared Saul J. PricemaniD· 2 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Handan Hong

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Radioligand therapy in combination with CAR T cells overcomes the heterogeneous immunosuppressive prostate tumor microenvironment

Jiangyue Liu, Iveta Fajnorovà, Yuwei Ren, Kofi Poku, S M Yang, Yu-Hsuan Fu, Cari A. Young, Lupita Lopez, Reginaldo Rosa, Handan Hong, Jingting Hao, Deyi Chen, Pauline Jeanjean, Ines Camille Azrour, Ava Fakharpour, , Saul J. Priceman

Combining 177Lu-PSMA-617 radioligand therapy with PSCA-CAR T cells improves tumor control and survival in prostate cancer models by overcoming antigen heterogeneity and reshaping the immunosuppressive tumor microenvironment.

bioRxiv · Jul 3, 2026 · PreprintCancer Biology

Focal radiotherapy improves CAR T cell therapy targeting prostate cancer

Cari A. Young, Jiangyue Liu, Yuwei Ren, Reginaldo Rosa, Lea Christian, Handan Hong, Lupita Lopez, Alyssa J. Buckley, Jingting Hao, Yukiko Yamaguchi, Anthony Park, Hemendra Ghimire, Amr M H Abdelhamid, Darren M. Zuro, Susanta Kumar Hui, , Saul J. Priceman

This study combines focal radiotherapy, cyclophosphamide, and PSCA-CAR T cells to enhance antitumor responses and survival in prostate cancer models.

bioRxiv · Jun 24, 2026 · PreprintCancer Biology